Plain-English translation of NCT06615193 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a first-in-human study testing a new medication called to see if it is safe and effective for people with B-cell lymphoma or advanced solid tumors that have not responded to previous treatments. Researchers will start with lower doses and gradually increase them to find the safest and most effective dose. The goal is to understand how well this new treatment works and what side effects patients experience.
Many patients with relapsed or refractory blood and solid cancers run out of effective treatment options. This medication aims to target cancer cells in a new way, potentially offering hope to patients whose cancers have stopped responding to standard therapies.
You likely qualify if…
You likely don't qualify if…
You will receive as an intravenous injection on the first day of repeated 21-day cycles. In the first phase, doctors will gradually increase your dose to find the safest level; in the second phase, you will receive the recommended dose. Throughout the study, you will have regular visits for blood tests, imaging scans, and physical exams to monitor how you respond and to check for side effects. You will also need to provide tissue samples (either archived or fresh) for testing before the study begins.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China